论文部分内容阅读
目的探讨四硝酸戊赤藓醇(PTEN)和小鼠核因子κB亚基p65亲和肽(NFκB p65)在上皮性卵巢癌中的表达以及与患者顺铂耐药性及预后的关系。方法选取2009年1月-2015年12月在河北医科大学第四医院妇产科治疗的161例上皮性卵巢癌患者,并根据患者对顺铂化疗的敏感性分为敏感组82例和耐药组79例。免疫组化检测患者肿瘤组织中PTEN和NFκB p65蛋白的表达,分析PTEN和NFκB p65蛋白表达与上皮性卵巢癌患者顺铂耐药的关系。Cox回归模型分析上皮性卵巢癌患者预后的独立危险因素。结果 68.29%的敏感组患者肿瘤组织中表达NFκB p65蛋白,明显低于耐药组患者(94.94%);50.0%的敏感组患者肿瘤组织中表达PTEN蛋白,明显高于耐药组患者(17.72%)。上皮性卵巢癌患者卵巢组织中NFκB p65蛋白表达与PTEN蛋白呈显著负相关(r_s=-0.246,P=0.002)。NFκB p65和PTEN蛋白以及手术分期是卵巢癌患者发生耐药的独立危险因素(P<0.05)。结论 PTEN蛋白低表达或NFκB p65蛋白高表达是上皮性卵巢癌患者发生耐药性的独立危险因素。
Objective To investigate the expression of PTEN and NFκB p65 in epithelial ovarian cancer and its relationship with cisplatin resistance and prognosis in patients with ovarian cancer. Methods A total of 161 patients with epithelial ovarian cancer treated by Department of Obstetrics and Gynecology, the Fourth Hospital of Hebei Medical University from January 2009 to December 2015 were enrolled. According to their sensitivity to cisplatin chemotherapy, 82 patients were divided into sensitive group and resistant group Group of 79 cases. The expression of PTEN and NFκB p65 in the tumor tissue was detected by immunohistochemistry and the relationship between the expression of PTEN and NFκB p65 protein and cisplatin resistance in patients with epithelial ovarian cancer was analyzed. Cox regression model analysis of epithelial ovarian cancer prognostic independent risk factors. Results The expression of NFκB p65 protein in tumor tissues was significantly lower in 68.29% of sensitive patients than that of drug-resistant patients (94.94%). The expression of PTEN protein in 50.0% of sensitive patients was significantly higher than that in drug-resistant patients (17.72% ). The expression of NFκB p65 protein in ovarian epithelial ovarian cancer patients was negatively correlated with PTEN protein (r_s = -0.246, P = 0.002). The NFκB p65 and PTEN protein and surgical staging were independent risk factors of drug resistance in ovarian cancer patients (P <0.05). Conclusion The low expression of PTEN protein or high expression of NFκB p65 protein is an independent risk factor for drug resistance in epithelial ovarian cancer patients.